Overview
I have been doing neuroscience and pain research for over 25 years in multiple academic institutes, including Duke University (2012-current), Harvard Medical School (1998-2012), Johns Hopkins Medical School, Karolinska Institute, and Peking University. The long-term goal of my lab is to identify molecular and cellular mechanisms that underlie the induction and resolution of pathological pain and develop novel pain therapeutics that can target these mechanisms, with specific focus on neuroimmune interactions. We are interested in the following scientific questions. (1) How does inflammation induce and resolve pain via immune cell interaction with primary sensory neurons? (2) How does neuroinflammation drive chronic pain via activation of glial cells in the CNS (microglia and astrocytes) and PNS (satellite glial cells) and regulation of sensory neuron plasticity (peripheral sensitization) and spinal cord synaptic plasticity (central sensitization)? (3) How do specialized pro-resolution mediators (SPMs, e.g., resolvins, protectins, and maresins) control pain via GPCR signaling? (4) How do immunotherapies through the PD-L1/PD-1 and STING/IFN pathways regulate pain, cognition, and neuronal activities? (5) How do secreted miRNAs regulate pain and itch via direct activation of surface receptors and ion channels? (6) How do nerve terminals interact with cancers in chronic pain and itch? (7) How do Toll-like receptors (TLR) in primary sensory neurons sense danger signals and regulate pain and itch? (8) How do regenerative approaches such as autologous conditioned serum (ACS) and bone marrow stromal cells (MSCs) produce long-term pain relief via secreting anti-inflammatory factors and exosomes? We employ a multidisciplinary approach that covers in vitro, ex vivo, and in vivo studies for animal behaviors, electrophysiology, molecular biology, cell biology, and transgenic animals. We have identified numerous therapeutic targets and filed many patents for translational studies. As the Director of the Center for Translational Pain Medicine (CTPM) and a highly cited researcher (Cross Field, Clarivate), I have both administrative and scientific leadership for successful completion of many research projects.
Current Appointments & Affiliations
Recent Publications
Primary Afferent Inhibition: An Underappreciated Mechanism in Mechanical Pain Control.
Journal Article Anesthesiology · April 1, 2026 Full text Link to item CiteAdditive Accelerated Meloxicam Release from Poly(Ester Urea) Fiber Implants for Acute Pain Management.
Journal Article Adv Healthc Mater · February 2026 Current clinical pain management strategies rely heavily on orally prescribed opioids, especially oxycodone, as opposed to non-steroidal anti-inflammatory drugs (NSAIDs) or local anesthetics. Implanted devices that facilitate controlled, localized delivery ... Full text Link to item CiteNPD1/GPR37 signaling protects against painful traumatic brain injury and comorbidities by regulating demyelination, glial responses, and neuroinflammation in the mouse brain.
Journal Article Brain Behav Immun · February 2026 Traumatic brain injury (TBI) often leads to neuropathic pain and a range of comorbidities, including post-traumatic stress disorder (PTSD), cognitive decline and depression. Neuroprotectin D1 (NPD1), a lipid mediator derived from the omega-3 fatty acid doc ... Full text Link to item CiteRecent Grants
JAK Specific Signaling in PTOA-associated Joint Degeneration and Pain
ResearchCo Investigator · Awarded by National Institutes of Health · 2025 - 2030Neurobiology Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institute of Neurological Disorders and Stroke · 2024 - 2029TRPM8 in eye health and disease
ResearchCo Investigator · Awarded by National Institutes of Health · 2020 - 2029View All Grants